Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Walmart Stores Inc (WMT) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Walmart (WMT) trades at $112.28, down 0.71% on the day, with a bullish technical signal from moving averages but overbought short-term RSI. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.81 exceeding the $0.742 estimate. Revenue growth is robust, reaching $681.0B in 2025, and analyst sentiment is overwhelmingly positive with a 71.21% buy rating. Recent news highlights expansion in AI capabilities, Marketplace growth over 50%, and a new Medicare Advantage partnership.

The outlook for WMT remains favorable driven by digital growth and market share gains, though valuation multiples like a P/E of 40.68 pose a risk if execution falters. Key opportunities include e-commerce expansion and cost efficiencies, while risks involve inflationary pressures and rising capital expenditures. The consensus price target of $128.84 suggests ~15% upside from current levels.